Oculis Holding AG

NASDAQ (USD): Oculis Holding AG (OCS)

Last Price

11.68

Today's Change

-0.01 (0.08%)

Day's Change

11.52 - 11.70

Trading Volume

5,046

Profile
OCS

Exchange:  NASDAQ Global Market NASDAQ Global Market

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Dr. Riad Sherif M.B.A., M.D. Dr. Riad Sherif M.B.A., M.D.

Full Time Employees:  36 36

IPO Date:  2021-05-18 2021-05-18

CIK:  0001953530 0001953530

ISIN:  CH1242303498 CH1242303498

CUSIP: 

Beta:  0.08 0.08

Last Dividend:  0.00 0.00

Dcf Diff:  11.25 11.25

Dcf:  0.36 0.36

Description

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

Address

Bahnhofstrasse 7,
Zug, 6300, CH

41 58 810 0182

http://oculis.com

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment